To find out more about RetroSense Therapeutics, please click through to the Contact Us page. We are currently seeking accredited financial partners and strategic partners interested in collaborating with us to develop our lead candidate.
RetroSense Therapeutics is a biotechnology company that is developing a game-changing gene therapy to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved therapies to improve or restore vision in patients with these retinal degenerative conditions.
The RetroSense gene therapy technology has been demonstrated to confer light sensitivity to retinal nerve cells and restore functional vision in animal studies. Our lead product candidate, RST-001, will be developed initially for RP with advanced dry-AMD as a follow-on indication. RST-001 is not currently in human clinical trials. Please visit us periodically to see how we are making progress in vision restoration.
March 5, 2013: Press Release
RetroSense Therapeutics Announces Notice of Allowance for New U.S. Patent Application Broadly Covering Optogenetic Approaches to Vision Restoration
February 18, 2013: Article
How Neuroscience Will Fight Five Age-Old Afflictions
October 4, 2012: Press Release
RetroSense Therapeutics Welcomes Dr. Steven Bramer as Chief Development Officer
August 28, 2012: Article
Company Aims to Cure Blindness with Optogenetics
June 6, 2012: Article
Optogenetics Workshop Sheds Light on Opportunities for Restoring Vision
May 24, 2012: Press Release
RetroSense Therapeutics Completes pre-IND Meeting for RST-001